Clinical Trial: Testing RG1-VLP Vaccine to Prevent HPV-related Cancers
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Human Papillomavirus-Related Carcinoma
Study Type: INTERVENTIONAL
Official Title: A Dose Escalation Phase I Trial of the Safety and Immunogenicity of RG1-VLP, a Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated Cancer
Brief Summary:
This phase I trial tests the safety, side effects, and best dose of RG1-virus-like particle (VLP) in preventing human papillomavirus (HPV)-related cancers in women.RG1-VLP is a vaccine that aims to protect against rare HPV types not targeted by currently approved HPV vaccines.HPV is a common sexually-transmitted infection that can cause certain genital and oral cancers.RG1-VLP contains a protein of HPV type 16 (HPV16) with a slightly different structure than the licensed Gardasil-9 vaccine.Gardasil-9 is approved…
Read more